| 0 (0%) | 04-25 17:09 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 77.43 | 1-year : | 90.44 |
| Resists | First : | 66.3 | Second : | 77.43 |
| Pivot price | 62.08  |
|||
| Supports | First : | 59.25 |
Second : | 54.9 |
| MAs | MA(5) : | 64.9 |
MA(20) : | 60.58 |
| MA(100) : | 55.79 |
MA(250) : | 57.85 |
|
| MACD | MACD : | 2.7  |
Signal : | 2.4 |
| %K %D | K(14,3) : | 85.6 |
D(3) : | 89.4 |
| RSI | RSI(14): 63.5 |
|||
| 52-week | High : | 66.98 | Low : | 20.1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CSR ] has closed below upper band by 27.5%. Bollinger Bands are 28% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 64.69 - 65.02 | 65.02 - 65.29 |
| Low: | 63.12 - 63.47 | 63.47 - 63.75 |
| Close: | 63.82 - 64.37 | 64.37 - 64.81 |
Tue, 23 Apr 2024
Optical Coherence Tomography-Based Positive Predictors of Eplerenone Therapy in Chronic Central Serous ... - Cureus
Thu, 11 Apr 2024
Motorcycle drivers reminded to stay in outer lanes - Inquirer.net
Thu, 11 Apr 2024
CSCR-CMC Vellore Junior Research Fellow Recruitment – Applications Invited - BioTecNika
Fri, 19 Jan 2024
Traffic light installed along SRP highway - SunStar Philippines
Mon, 11 Sep 2023
5 Myths About Amnesty - Newark - University of Delaware
Tue, 29 Aug 2023
Ocular steroidome in human eyes and in eyes with complex central serous chorioretinopathy (CSCR) | Scientific Reports - Nature.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 15 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 81.9 (%) |
| Shares Short | 196 (K) |
| Shares Short P.Month | 174 (K) |
| EPS | 2.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 41.18 |
| Profit Margin | 16 % |
| Operating Margin | 4.8 % |
| Return on Assets (ttm) | 0.7 % |
| Return on Equity (ttm) | 5.1 % |
| Qtrly Rev. Growth | -5.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 17.54 |
| EBITDA (p.s.) | 8.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 90 (M) |
| Levered Free Cash Flow | 101 (M) |
| PE Ratio | 27.72 |
| PEG Ratio | -11.3 |
| Price to Book value | 1.56 |
| Price to Sales | 3.66 |
| Price to Cash Flow | 10.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|